Helicobacter pylori promotes inflammatory factor secretion and lung injury through VacA exotoxin-mediated activation of NF-κB signaling

Meizhu Chen\textsuperscript{a}, Xueping Huang\textsuperscript{b,c}, Minzhao Gao\textsuperscript{a}, Zhipeng Yang\textsuperscript{e}, Zhaoxiong Fang\textsuperscript{d}, Jinqi Wei\textsuperscript{d}, and Baihe Wu \textsuperscript{d}

\textsuperscript{a}Department of Pulmonary and Critical Care Medicine (PCCM), The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China; \textsuperscript{b}Department of Gastroenterology, Fujian Provincial Hospital, Fuzhou, China; \textsuperscript{c}Department of Gastroenterology, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China; \textsuperscript{d}Department of Gastroenterology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China; \textsuperscript{e}Department of Gastroenterology, Dongguan Tungwah Hospital, DongGuan, China

ABSTRACT

Previous reports have shown that Helicobacter pylori (H. pylori) infection is associated with respiratory diseases. However, the pathogenesis remains unclear. Vacuolating cytotoxin A (VacA) is a major H. pylori exotoxin. In this study, we investigated the signaling pathways involved in the inflammatory response to H. pylori infection and VacA. Mice were treated with H. pylori and VacA, and histopathological analysis of lung tissues was performed using hematoxylin-eosin, Masson’s trichrome, and periodic acid Schiff staining. The secretion of inflammatory cytokines was evaluated by enzyme-linked immunosorbent assay. The expression of VacA, nuclear factor-kappa B (NF-κB), and p65 NF-κB was analyzed by Western blotting and immunofluorescence. Cell proliferation and apoptosis were assessed using the MTS assay and flow cytometry, respectively. In mice, H. pylori infection and VacA treatment promoted the secretion of the inflammatory factors interleukin 1β (IL-1β), tumor necrosis factor α (TNF-α), IL-6, and IL-8, increased p65 NF-κB protein phosphorylation, and induced lung injury. Furthermore, H. pylori infection promoted VacA production. In an in vitro cell model, VacA treatment significantly suppressed the proliferation of WI-38 and BEAS-2B cells, promoted apoptosis, induced TNF-α, IL-1β, IL-6, and IL-8 secretion, and promoted p65 NF-κB protein phosphorylation and NF-κB nuclear transfer. The NF-κB inhibitor BAY11-7082 alleviated VacA-induced inflammation and apoptosis and increased cell viability. In conclusion, VacA promotes the secretion of inflammatory factors and induces lung injury through NF-κB signaling.

CONTACT Baihe Wu \textsuperscript{d} wubaihe@mail.sysu.edu.cn; Jinqi Wei \textsuperscript{d} weijinqi@mail.sysu.edu.cn Department of Gastroenterology, The Fifth Affiliated Hospital of Sun Yat-sen University, No. 52 Meihua Road, Xiangzhou District, Zhuhai 519000, Guangdong, China

\textsuperscript{d}Contributed equally to this paper.

Supplemental data for this article can be accessed online at https://doi.org/10.1080/21655979.2022.2071011

© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Highlights

- *H. pylori* infection and VacA treatment enhanced lung injury in mice.
- *H. pylori* infection promotes VacA production in mice.
- VacA treatment promotes the secretion of the inflammatory factors.
- VacA treatment activates NF-κB pathway.

Introduction

*Helicobacter pylori* (*H. pylori*) infection is closely associated with various human gastric diseases, such as gastritis, gastric ulcers, gastric atrophy, and gastric cancer [1–3]. Approximately half of the global population is infected with *H. pylori*, resulting in high mortality [4]. Recently, *H. pylori* infection was found to be related to extra-digestive diseases, such as autoimmune, respiratory, and cardiovascular diseases [5,6]. Inflammation caused by *H. pylori* infection is considered the main cause of these diseases [7]; Arismendi et al. reported that *H. pylori* infection leads to lung injury by recruiting inflammatory cells and promoting the secretion of inflammatory cytokines, which induces morphological changes in the lung tissue [8]. However, the mechanisms by which *H. pylori* infection causes respiratory diseases remain unclear. Vacuolating cytotoxin A (VacA), a major exotoxin of *H. pylori*, can induce vacuolation, inhibit T cell function, regulate autophagy, and promote cell death [9,10]. Recently, Nakashima et al. [11] found that VacA promotes the secretion of interleukin-8 (IL-8) and interleukin-6 (IL-6), potentially inducing respiratory diseases. Therefore, VacA may be the main factor in *H. pylori*-mediated respiratory diseases.

*H. pylori* infection induced lung injury via increasing the expression of inflammatory mediators using a mouse model [8]. *H. pylori* stimulates immune response and long-term inflammation which may be one of the causes of lung injury in the human body [12]. *H. pylori* infection activated NF-κB signaling pathway leading to the deleterious gastric pathophysiology and gastric diseases [13]. The nuclear factor-kappa B (NF-κB) pathway is closely associated with inflammatory cytokine secretion, which has a positive feedback–based regulatory relationship with inflammatory factors such as interleukin 1β (IL-1β) and tumor necrosis factor α (TNF-α) [14]. VacA promoted inflammatory cytokine secretion and cell apoptosis in human monocytic cell line via the activation of NF-κB [15]. These studies have shown that *H. pylori* infection and VacA treatment can activate the NF-κB signaling pathway to promote the expression and secretion of inflammatory factors. However, whether *H. pylori* infection and VacA treatment causes lung injury via the NF-κB pathway remains unknown.

This study hypothesized that VacA, a major *H. pylori* exotoxin, promote inflammatory cytokine secretion and lung injury via regulating NF-κB signaling pathway. In this study, we investigated the pulmonary effects of *H. pylori* infection and VacA treatment in mice and evaluated the molecular mechanisms of the NF-κB signaling pathway. In addition, we verified the injury-inducing effect and mechanism of action of VacA *in vitro* in WI-38 and BEAS-2B cells. By clarifying the mechanism of *H. pylori* infection, this study may provide a foundation for identifying novel therapeutic targets.

Methods

Animals

Male BALB/c wild-type (WT) mice (6–12 weeks old), weighing approximately 25–30 g, were obtained from the Medical Experimental Animal Center of the Laboratory Animal Management Center of Southern Medical University. The mice had free access to sterile food and water during the entire experimental period and were maintained under a 12 h/12 h light/dark cycle at 25°C. All animal experiments were approved by the Fifth Affiliated Hospital of Sun Yat-sen University (Approval time: 23 March 2021).

Bacteria, *H. pylori* infection, and VacA treatment

*H. pylori* strain NCTC 11638 (National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China) was grown and prepared as described previously [8]. Briefly, $2 \times 10^8$ CFU/mL of bacterial suspension was
used to infect the mice. VacA (recombinant VacA protein, \textit{H. pylori} A210016, Baiaolaibo, Beijing, China) was dissolved in phosphate buffered saline (PBS). Mice were divided into four groups of six: normal, \textit{H. pylori}-infected, negative control (NC), and VacA-treated. In the normal group, the mice received no treatment. In the \textit{H. pylori}-infected group, 50 μL of bacterial suspension was administered by orotracheal instillation once a day for 3 d. In the VacA-treated group, 10 mg/mL of VacA was administered by orotracheal instillation once a day for 3 d. In the NC group, an equal amount of sterile 1× PBS (pH 7.4) was administered once a day for 3 d. After 14 d, the mice were sacrificed. Blood samples were collected for cytokine analysis, and lung tissue samples were quickly harvested and snap frozen in liquid nitrogen until analysis.

**Histopathological analysis of lung tissues**

Hematoxylin-eosin (H&E), Masson’s trichrome, and periodic acid Schiff (PAS) staining kits were obtained from Solarbio Life Science (Beijing, China) [16]. Harvested lung tissue samples were fixed and mounted. Sections were then stained, and histopathological analysis was performed using light microscopy (Olympus, Tokyo, Japan). Five fields per sample were analyzed.

**Immunofluorescence assay**

For the immunofluorescence assay, sections of lung tissue were incubated first with anti-p65 NF-κB antibody (Abcam, Cambridge, MA, USA; 1:100) and then with secondary antibody (Abcam; 1:3000) at 37°C for 1 h, after which they were counterstained with DAPI [17]. Samples were observed under a fluorescence microscope (Olympus CX23, Tokyo, Japan).

**Western blotting**

For Western blotting, total protein was separated by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes (Millipore, Atlanta, GA, USA) [17]. After washing and blocking, the membranes were incubated with primary antibodies against VacA (sc-32,746, Santa Cruz Biotechnology, Santa Cruz, CA, USA, 1:500), p65 NF-κB (ab32536, 1:5000), p-p65 NF-κB (ab76302, 1:1000), and GAPDH (ab8245; Abcam, 1:10,000). After washing again, the membranes were incubated with secondary antibody (ab205718 and ab6728; Abcam, 1:10,000) for 2 h at 25°C. Protein bands were detected using an enhanced chemiluminescence kit (Pierce, Rockford, IL, USA).

**RT-qPCR**

For RT-qPCR, the relative expression level of CNN3 was calculated using the $2^{-\Delta\Delta CT}$ method [18]. The expression of TNF-α, IL-1β, IL-6, and IL-8 was measured by qRT-PCR using SYBR GREEN qPCR Super Mix (Invitrogen). Primers as follows: GAPDH: 5’-GCTCATTTGCAGGGGGGAG-3’ and 5’-GTGTGGTGTGCAGGAGGCA-3’; IL-1β: 5’-CTTGGGTGATGTCTGGTCCAT-3’ and 5’-CCTTGTACAAAGGACATGGAG-3’; TNF-α: 5’-GCTCATTTGCAGGGGGAG-3’ and 5’-GTTGGTGATGTCTGGTCCAT-3’ and 5’-AGCTTCGTCAGCAGGC-3’; IL-8: 5’-AGATGCGAAAGACCATGACG-3’ and 5’-GCAGAAGCTGTGCAGATGAGT-3’ and 5’-GTTGGTGATGTCTGGTCCAT-3’.

**Luciferase activity assay**

The procedure of Luciferase activity assay is shown in previous studies [19]. Briefly, WI-38 and BEAS-2B cells were transiently cotransfected with NF-κB reporter and TK Renilla luciferase plasmids using Lipofectamine™ 2000 (Invitrogen). After culture 24 h, the luciferase activity of the supernatant was detected using a Dual-luciferase reporter assay system, and relative fluorescence reporter activity were designated as the activity of firefly luciferase normalized to that of Renilla luciferase.

**ELISA**

TNF-α, IL-1β, IL-6, and IL-8 levels in blood samples and cell culture supernatants were measured using ELISA. All ELISA kits were purchased from Bios (Beijing, China).
Cell treatment

WI-38 and BEAS-2B cells were cultured in 6-well plates at a density of $1.0 \times 10^5$ cells per well. The cells were divided into three groups: normal, VacA-treated, and negative control (NC). In the normal group, cells were cultured normally. In the VacA-treated group, 1 μg/mL VacA (final concentration) was added to the medium. In the NC group, an equal amount of PBS was added to the medium. Next, the NF-κB inhibitor BAY11-7082 was used to investigate the relationship between VacA and NF-κB. In the VacA + inhibitor group, 1 μg/mL VacA and 5 μmol/L BAY11-7082 (final concentration) were added to the medium. In the VacA + PBS group, VacA (1 μg/mL) and PBS were added to the medium. After 48 h of incubation, the cells and culture supernatants were collected by centrifugation. Three independent experiments were performed.

Cell proliferation and apoptosis assays

After treatment, the CellTiter 96® AQueous One Solution Cell Proliferation Assay kit (MTS assay; Promega, Madison, WI, USA) was used to evaluate cell proliferation. Cells were double-stained using the Annexin V-FITC Apoptosis Detection Kit (Keygentec, Nanjing, China), following the manufacturer’s instructions. The percentage of apoptotic cells was assessed by NovoCyte 4025 flow cytometry and NovoExpress software analysis (ACEA Biosciences, Agilent, Hangzhou, China). The original images of apoptosis were shown in Supplementary 4_flow apoptosis pictures.

Statistical analysis

Statistical analysis was performed using SPSS 22.0 statistical software (IBM Corp., Armonk, NY, USA). All data conformed to a normal distribution and are expressed as the mean ± standard deviation (SD). Differences among the normal, H. pylori-infected, NC, and VacA-treated groups were analyzed using Student’s t-test. Comparisons among the normal, NC, and VacA-treated groups and among the VacA, VacA + PBS, and VacA + inhibitor groups were performed using one-way analysis of variance (ANOVA) followed by Dunnett’s test. Statistical significance was set at $P < 0.05$.

Results

Histopathological analysis of lung tissues

To study the pulmonary effect of H. pylori infection and VacA treatment in mice, histological analysis of lung tissues was performed using H&E, Masson’s trichrome, and PAS staining. H&E staining indicated significant alveolar hemorrhage, inflammatory cell infiltration, and alveolar fusion in the pulmonary tissue of the H. pylori-infected group, compared to that of the normal group. Masson’s staining produced blue-colored connective tissues in the H. pylori-infected group, indicating obvious fibrosis in the pulmonary tissue. PAS staining revealed the presence of macrophages in lung tissue in the H. pylori-infected group (Figure 1). The NC group exhibited results similar to those of the normal group and the VacA-treated group exhibited results similar to those of the H. pylori-infected group (Figure 1).

H. pylori infection and VacA treatment promoted expression of inflammatory factors and NF-κB signaling in mice

To determine the effect of H. pylori infection and VacA treatment on the expression of inflammatory factors, ELISA was used to measure the expression of TNF-α, IL-1β, IL-6, and IL-8 in the serum of mice infected with H. pylori and treated with VacA. Compared to the normal and NC groups, the H. pylori-infected group exhibited increased levels of TNF-α, IL-1β, IL-6, and IL-8; these effects were also observed in the VacA-treated group (Figure 2a). Compared to the normal and NC groups, the H. pylori-infected group exhibited higher levels of VacA and p-p65 NF-κB proteins, but p65 NF-κB protein levels were unaffected. Similar results were found in the VacA-treated group (Figure 2b). Immunofluorescence assay results showed that H. pylori infection and VacA treatment promoted the transfer of NF-KB from the cytoplasm to the nucleus (Figure 2c).
VacA treatment suppressed proliferation and promoted apoptosis of lung cells

To study the effect of VacA treatment on lung cell proliferation, the viability of WI-38 and BEAS-2B cells after VacA treatment for 48 h was measured via MTS assay. Compared to that in the normal and NC groups, cell viability was significantly suppressed in the VacA treatment group (Figure 3a and 3c). Moreover, VacA treatment significantly promoted apoptosis (Figure 3b and 3d).

VacA treatment promoted expression of inflammatory factors and NF-κB signaling in lung cells

To analyze the effect of VacA treatment on the expression of inflammatory factors in lung cells, the levels of TNF-α, IL-1β, IL-6, and IL-8 in the culture supernatants of VacA-treated WI-38 and BEAS-2B cells were measured by ELISA and qRT-PCR. Compared to those in the normal and NC groups, the levels of TNF-α, IL-1β, IL-6, and IL-8 were significantly increased in the VacA-treated group (Figure 4a and 4b). Compared to the normal group, the VacA-treated group exhibited significantly higher p-p65 NF-κB protein expression, whereas p65 NF-κB protein expression remained unchanged, suggesting that VacA treatment significantly enhanced the phosphorylation of p65 NF-κB protein (Figure 4c). Luciferase activity assay found that the reporter activity of NF-κB in both WI-38 and BEAS-2B cells was significantly activated after VacA treatment (Figure 4d). Additionally, immunofluorescence and western blot assay results showed that p65 NF-κB protein expression in the nucleus was obviously enhanced after VacA treatment (Figure 4e and 4f).

The NF-κB signaling pathway is regulated by VacA

To determine whether NF-κB is a downstream pathway regulated by VacA, cells were incubated with both NF-κB inhibitor and VacA protein. The p-p65 NF-κB protein level was significantly reduced, whereas the p65 NF-κB protein level remained...
unchanged in the VacA + inhibitor group compared to that in the VacA and VacA + PBS groups (Figure 5a). Additionally, immunofluorescence and western blot assay results showed that p65 NF-κB protein expression in the nucleus was obviously reduced in the VacA + inhibitor group (Figure 5b and 5c). Compared to those in the VacA and VacA + PBS groups, the levels of TNF-α, IL-1β, IL-6, and IL-8 in the cell and culture supernatants of WI-38 and BEAS-2B cells were significantly decreased in the VacA + inhibitor group (Figure 5d and 5e). In addition, compared to that in the VacA and VacA + PBS groups, the viability of WI-38 and BEAS-2B cells in the VacA + inhibitor group was significantly enhanced, whereas apoptosis was significantly suppressed (Figure 6).
Discussion

Recently, *H. pylori* infection has been associated with many extra-digestive diseases, including respiratory diseases [20,21]. In the present study, *H. pylori* infection and VacA treatment induced morphological changes and lung tissue injury in mice. *H. pylori* infection and VacA treatment also promoted the secretion of the inflammatory factors TNF-α, IL-1β, IL-6, and IL-8, in addition to increasing p65 NF-κB protein expression. In the *in vitro* lung cell model, VacA treatment significantly suppressed cell viability, promoted apoptosis, and induced TNF-α, IL-1β, IL-6, and IL-8 production. VacA treatment also significantly promoted p65 NF-κB protein expression. The NF-κB inhibitor BAY11-7082 alleviated VacA-induced inflammation and apoptosis and enhanced cell viability. These data clearly indicate that *H. pylori* VacA promotes inflammatory factor secretion and endothelial dysfunction through the NF-κB signaling pathway, resulting in lung injury.

Recently, the association between *H. pylori* infection and certain extra-gastric manifestations, such as chronic respiratory diseases, has been investigated [22–24]. *H. pylori* DNA has been found in the bronchoalveolar lavage fluid from lung cancer patients and in lung biopsy specimens, suggesting that *H. pylori* exists in lung tissues [25]. *H. pylori* infection enhances the mRNA expression of TNF-α, IL-1β, MMP9, I-CAM, V-CAM, and IL-8 in lung tissues and promotes lung injury [8]. Similarly, we found that the lung samples from *H. pylori*-infected mice featured morphological changes and injury, and the same effects were observed following VacA treatment. These result suggest that VacA is a major *H. pylori* virulence factor in lung injury. Previous study found that cag-pathogenicity Island is an established *H. pylori* virulence factor which can enhance inflammatory response and promote gastric cancer [26], suggest that different virulence factors play a key role in different diseases. Furthermore, *H. pylori* infection enhanced VacA production in mice with lung injury, suggesting that *H. pylori* infection may cause damage via the VacA protein. *H. pylori* infection and VacA treatment also promoted the secretion of the inflammatory factors TNF-α, IL-1β, IL-6, and IL-8 in mouse serum. Subsequently, the mechanism of VacA-mediated injury was verified in *vitro* in WI-38 and BEAS-2B cells. The viability and apoptosis rate of human bronchial epithelial cells are important indicators of lung cell function. We found that infection significantly suppressed the viability of lung cells and promoted
apoptosis, indicating that VacA treatment leads to bronchial epithelial cell dysfunction. Nakashima et al. reported that VacA treatment promotes IL-6 and IL-8 secretion in lung cells, leading to respiratory diseases in predisposed individuals [11]. Similarly, we found that VacA treatment induced TNF-α, IL-1β, IL-6, and IL-8 production in WI-38 and BEAS-2B cells, supporting the hypothesis that the lung epithelium is responsive to pathogenic factors of *H. pylori*.

The NF-κB pathway has been associated with severe inflammatory diseases [27,28]. We found that *H. pylori* infection and VacA treatment promoted p65 NF-κB protein phosphorylation and
NF-κB nuclear transfer. These results suggest that NF-κB signaling may play a vital role in the inflammatory response and lung injury induced by *H. pylori* infection in mice. Furthermore, these findings indicate that *H. pylori* infection promotes inflammatory factor secretion, activates NF-κB signaling, and induces lung injury via the VacA exotoxin. VacA treatment significantly promoted p65 NF-κB protein phosphorylation and NF-κB nuclear transfer in WI-38 and BEAS-2B cells. The NF-κB inhibitor BAY11-7082 alleviated VacA-induced inflammation and apoptosis and enhanced cell viability. Therefore, the VacA exotoxin may promote inflammatory secretion and cell apoptosis and inhibit cell viability by activating NF-κB signaling. Combined with the results of the animal experiments, we concluded that VacA is a functional *H. pylori* protein that activates the NF-κB signaling pathway, promoting the secretion of inflammatory factors and thereby inhibiting the survival of lung
Figure 6. Alleviation of VacA-induced apoptosis and suppression of viability by the NF-κB inhibitor BAY11-7082. (a and c) Viability of WI-38 and BEAS-2B cells after VacA treatment was assessed by MTS assay. (b and d) Apoptosis of WI-38 and BEAS-2B cells after VacA treatment was assessed by flow cytometry. (vs VacA group, *P < 0.05, vs VacA + PBS group, #P < 0.05).

cells. Previous study found that VacA secreted by *H. pylori* was recognized as pattern-recognition receptors by the toll-like receptors, NOD-like receptors, RIG-I like receptors, and C-type lectin receptors [29]. Then it can promote inflammatory cytokine secretion and cell apoptosis via activating TRAF6/IRAK4/IKKα/NF-κB pathway and promoting NF-κB nuclear transfer [29,30]. It may be the mechanism by which VacA activates NF-KB to promote the secretion of inflammatory factors in lung cells. However, this mechanism needs to be further proved. In addition, studies have shown that VacA can also regulate mitogen-activated protein kinase pathway, phosphorylation of protein kinase B pathway, and autophagy, which also had relationship with inflammation and cell apoptosis [31–33]. Therefore, whether VacA can regulate other signaling pathways in lung injury remains to be further investigated.

VacA is the main mediator of respiratory diseases caused by *H. pylori* and represents a potential therapeutic target.

**Acknowledgements**

None.

**Author contributions**

MC and XH: Conceptualization, Resources, Investigation, Project Administration, Data Curation, Visualization, and Writing - Original Draft; MG, ZY, and ZF: Project Administration and Data Curation; BW and JW: Project Administration; BW and JW: Formal Analysis, Investigation and Data Curation, and Writing - Review & Editing

**Disclosure statement**

No potential conflict of interest was reported by the author(s).

**Funding**

This work was supported by the Zhuhai Science and Technology Project (ZH22036201210072), Zhuhai Science and Technology Project (20181117E030040) and the Qihang
Foundation of Fujian Medical University No. 2016QH108 (No. 2016QH108).

Data Availability Statement
All date from this study are available in this published article.

ORCID
Baihe Wu http://orcid.org/0000-0002-7241-5139

References

[1] Burkitt MD, Duckworth CA, Williams JM. Helicobacter pylori -induced gastric pathology: insights from in vivo and ex vivo models. Dis Model Mech. 2017;10 (2):89–104.

[2] Wroblewski LE, Peek RM Jr. Helicobacter pylori, cancer, and the gastric microbiota. Adv Exp Med Biol. 2016;908:393–408.

[3] Pei Y, Tang Z, Cai M, et al. MicroRNA miR-425 promotes tumor progression by inhibiting Dickkopf-related protein-3 in gastric cancer. Bioengineered. 2021;12 (1):2045–2054.

[4] de Brito BB, da Silva FAF, Soares AS, et al. Pathogenesis and clinical management of Helicobacter pylori gastric infection. World J Gastroenterol. 2019;25 (37):5578–5589.

[5] Kyburz A, Müller A. Helicobacter pylori and Extragastric Diseases. Curr Top Microbiol Immunol. 2017;400:325–347.

[6] Wang F, Liu J, Zhang Y, et al. Association of Helicobacter pylori infection with chronic obstructive pulmonary disease and chronic bronchitis: a meta-analysis of 16 studies. Infect Dis (Lond). 2015;47(9):597–603.

[7] Salama NR, Hartung ML, Müller A. Life in the human stomach: persistence strategies of the bacterial pathogen Helicobacter pylori. Nat Rev Microbiol. 2013;11 (6):385–399.

[8] Arismendi Sosa AC, Salinas Ibáñez AG, Pérez Chaca MV, et al. Study of Helicobacter pylori infection on lung using an animal model. Microb Pathog. 2018;123:410–418.

[9] Palframan SL, Kwok T, Gabriel K. Vacuolating cytoxin A (VacA), a key toxin for Helicobacter pylori pathogenesis. Front Cell Infect Microbiol. 2012;2:92.

[10] Chambers MG, Pyburn TM, González-Rivera C, et al. Structural analysis of the oligomeric states of Helicobacter pylori VacA toxin. J Mol Biol. 2013;425(3):524–535.

[11] Nakashima S, Kagakawa T, Yura H, et al. Identification of Helicobacter pylori VacA in human lung and its effects on lung cells. Biochem Biophys Res Commun. 2015;460(3):721–726.

[12] Durazzo M, Adriani A, Fagoonee S, et al. Helicobacter pylori and respiratory diseases: 2021 update. Microorganisms. 2021;9(10):2033.

[13] Maubach G, Vieth M, Boccellato F, et al. Helicobacter pylori-induced NF-κB: trailblazer for gastric pathophysiology. Trends Mol Med. 2022;28(3):210–222.

[14] Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol. 2009;1 (6):a001651.

[15] Luo JJ, Li CY, Liu S, et al. Overexpression of Helicobacter pylori VacA N-terminal fragment induces proinflammatory cytokine expression and apoptosis in human monocytic cell line through activation of NF-κB. Can J Microbiol. 2013;59(8):523–533.

[16] Xie J, Yuan Y, Yao G, et al. Nucleoporin 160 (NUP160) inhibition alleviates diabetic nephropathy by activating autophagy. Bioengineered. 2021;12(1):6390–6402.

[17] Wang WB, Li JT, Hui Y, et al. Combination of pseudoephedrine and emodin ameliorates LPS-induced acute lung injury by regulating macrophage M1/M2 polarization through the VIP/cAMP/PKA pathway. Chin Med. 2022;17(1):19.

[18] Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402–408.

[19] Zhang L, Lv Y, Rong Y, et al. Downregulated expression of RACK1 results in pancreatic cancer growth and metastasis. Onco Targets Ther. 2019;12:1007–1020.

[20] de Korwin JD, Ianiro G, Gibiino G, et al. Helicobacter pylori infection and extragastric diseases in 2017. Helicobacter. 2017;22(Suppl 1):e12411.

[21] Lee HY, Kang HR, Lee JK, et al. The effect of Helicobacter pylori infection on the decline of lung function in a health screening population. Ann Palliat Med. 2020;9(5):3115–3122.

[22] He M, Zheng Y, Ma A, et al. Helicobacter pylori is associated with weakened pulmonary function and reduced incidence of allergic conditions in patients with chronic cough. Exp Ther Med. 2020;20(5):47.

[23] Wang L, Guan Y, Li Y, et al. Association between chronic respiratory diseases and Helicobacter pylori: a Meta-Analysis. Arch Bronconeumol. 2015;51(6):273–278.

[24] Dela Pena-Ponce MG, Jimenez MT, Hansen LM, et al. The Helicobacter pylori type IV secretion system promotes IL-8 synthesis in a model of pediatric airway epithelium via p38 MAP kinase. PLoS One. 2017;12(8):e0183324.

[25] Samareh-Fekri M, Hashemi Baigani SM, Shafahi A, et al. Detection of Helicobacter pylori in the Bronchoalveolar Lavage of Patients with Lung Cancer Using Real-Time PCR. Jundishapur J Microbiol. 2016;9 (11):e32144.

[26] Gopal GJ, Kumar A, Pal J, et al. Molecular characterization and polyclonal antibody generation against core component CagX protein of Helicobacter pylori type IV secretion system. Bioengineered. 2014;5(2):107–113.

[27] Sun SC. The non-canonical NF-κB pathway in immunity and inflammation. Nat Rev Immunol. 2017;17(9):545–558.
[28] Ma SQ, Wei HL, Zhang X. TLR2 regulates allergic airway inflammation through NF-κB and MAPK signaling pathways in asthmatic mice. Eur Rev Med Pharmacol Sci. 2018;22(10):3138–3146.

[29] Castaño-Rodríguez N, Kaakoush NO, Mitchell HM. Pattern-recognition receptors and gastric cancer. Front Immunol. 2014;5:336.

[30] Choi HR, Lim H, Lee JH, et al. Interruption of Helicobacter pylori -Induced NLRP3 Inflammasome Activation by Chalcone Derivatives. Biomol Ther (Seoul). 2021;29(4):410–418.

[31] Yang JY, Kim JB, Lee P, et al. Evodiamine Inhibits Helicobacter pylori Growth and Helicobacter pylori-Induced Inflammation. Int J Mol Sci. 2021;225 3385.

[32] Eslami M, Yousefi B, Kokhaei P, et al. Current information on the association of Helicobacter pylori with autophagy and gastric cancer. J Cell Physiol. 2019;234(9):14800–14811.

[33] Nakayama M, Hisatsune J, Yamasaki E, et al. Helicobacter pylori VacA-induced inhibition of GSK3 through the PI3K/Akt signaling pathway. J Biol Chem. 2009;284(3):1612–1619.